cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Spectrum Pharmaceuticals Inc
23 own
48 watching
Current Price
$1.11
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
225.14M
52-Week High
52-Week High
1.57
52-Week Low
52-Week Low
0.315
Average Volume
Average Volume
0.76M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization225.14M
icon52-Week High1.57
icon52-Week Low0.315
iconAverage Volume0.76M
iconDividend Yield--
iconP/E Ratio--
What does the Spectrum Pharmaceuticals Inc do?
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Read More
How much money does Spectrum Pharmaceuticals Inc make?
News & Events about Spectrum Pharmaceuticals Inc.
PR Newswire
1month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, NATI, SPPI SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, NATI, SPPI PR Newswire NEW YORK, May 2, 2023 NEW YORK, May 2, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following...
Globe Newswire
1month ago
NEW YORK, April 29, 2023 (GLOBE NEWSWIRE) -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of HOTH with Algorithm Sciences, Inc., whereby HOTH shareholders are expected to own approximately ...
PR Newswire
1month ago
Moore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law Firm Moore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law Firm PR Newswire NEW YORK, April 28, 2023 NEW YORK, April 28, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities...
Globe Newswire
1month ago
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)s...
Zolmax
1month ago
JMP Securities lowered shares of Spectrum Pharmaceuticals (NASDAQ:SPPI Get Rating) from an outperform rating to a market perform rating in a report issued on Wednesday morning, The Fly reports. SPPI has been the topic of several other reports. HC Wainwright reaffirmed a buy rating and set a $4.00 ...
Frequently Asked Questions
Frequently Asked Questions
What is Spectrum Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Spectrum Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Spectrum Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Spectrum Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Spectrum Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Spectrum Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Spectrum Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Spectrum Pharmaceuticals Inc?
plus_minus_icon
What percentage is Spectrum Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Spectrum Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.11
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
BeiGene Ltd
BeiGene Ltd
$227.36
$3.88 (1.74 %)
DBV Technologies S.A.
DBV Technologies S.A.
$1.99
$0.03 (1.53 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$21.53
$0.83 (4.01 %)
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$26.05
$0.34 (1.32 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
BeiGene Ltd
BeiGene Ltd
$227.36
$3.88 (1.74 %)
DBV Technologies S.A.
DBV Technologies S.A.
$1.99
$0.03 (1.53 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$21.53
$0.83 (4.01 %)
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$26.05
$0.34 (1.32 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00